Xeris Biopharma Holdings (XERS) Total Liabilities (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Total Liabilities came in at $379.0 million in Q1 2026, up 8.11% YoY from $350.6 million in Q1 2025, and up 2.48% on a QoQ basis from $369.8 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Total Liabilities (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Total Liabilities data on file, last reported at $379.0 million in Q1 2026.
- Quarterly Total Liabilities rose 8.11% year-over-year to $379.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $379.0 million (up 8.11% YoY) and the FY2025 annual result came in at $369.8 million, up 4.87% from the prior year.
- Total Liabilities grew to $379.0 million in Q1 2026, from $369.8 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $379.0 million in Q1 2026 to a low of $241.2 million in Q1 2022.
- A 5-year average of $324.5 million and a median of $345.8 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities jumped 85.44% — and 2025, when it increased 0.85%.
- Tracing XERS's Total Liabilities over 5 years: stood at $299.3 million in 2022, then rose by 10.04% to $329.4 million in 2023, then grew by 7.07% to $352.7 million in 2024, then grew by 4.87% to $369.8 million in 2025, then grew by 2.48% to $379.0 million in 2026.
- The last three Total Liabilities figures came in at $379.0 million (Q1 2026), $369.8 million (Q4 2025), and $371.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.12 Bn |
| 10 | Xeris Biopharma Holdings | 1.48 Bn | 1.36 Bn | 79.59 Mn | 421.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 421.64 Mn |
| Mar 31, 2026 | 379.00 Mn |
| Dec 31, 2025 | 369.84 Mn |
| Sep 30, 2025 | 371.05 Mn |
| Jun 30, 2025 | 353.99 Mn |
| Mar 31, 2025 | 350.58 Mn |
| Dec 31, 2024 | 352.68 Mn |
| Sep 30, 2024 | 349.43 Mn |
| Jun 30, 2024 | 351.02 Mn |
| Mar 31, 2024 | 345.79 Mn |
| Dec 31, 2023 | 329.38 Mn |
| Sep 30, 2023 | 323.92 Mn |
| Jun 30, 2023 | 315.14 Mn |
| Mar 31, 2023 | 291.31 Mn |
| Dec 31, 2022 | 299.34 Mn |
| Sep 30, 2022 | 247.98 Mn |
| Jun 30, 2022 | 244.67 Mn |
| Mar 31, 2022 | 241.17 Mn |
| Dec 31, 2021 | 209.13 Mn |
| Sep 30, 2021 | 133.72 Mn |